Citi Venture Capital International has sold its 87.2% stake in pharmaceutical company Sanitas, AltAssets reports. The deal values the Lithuanian company at about €365 million.
The sale represents Citi Venture’s fifth successful exit in the generic pharmaceutical space. Sanitas is a branded generic pharmaceutical company focused on specialty therapeutic segments.
Click here for the story from AltAssets.